Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Applied DNA Sciences Inc is a diagnostics & research business based in the US. Applied DNA Sciences shares (APDN) are listed on the NASDAQ and all prices are listed in US Dollars. Applied DNA Sciences employs 78 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $3.49 |
|---|---|
| 52-week range | $3.20 - $13.64 |
| 50-day moving average | $4.76 |
| 200-day moving average | $5.66 |
| Wall St. target price | $16.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.07 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.49 from 2022-01-26
| 1 week (2022-01-21) | -5.68% |
|---|---|
| 1 month (2021-12-28) | -18.08% |
| 3 months (2021-10-28) | -36.55% |
| 6 months (2021-07-28) | -33.78% |
| 1 year (2021-01-28) | -64.57% |
|---|---|
| 2 years (2020-01-28) | -10.28% |
| 3 years (2019-01-28) | 636.44% |
| 5 years (2017-01-27) | 83.68% |
| Revenue TTM | $9 million |
|---|---|
| Gross profit TTM | $4.9 million |
| Return on assets TTM | -59.65% |
| Return on equity TTM | -169.76% |
| Profit margin | -158.25% |
| Book value | $1.49 |
| Market capitalisation | $25.2 million |
TTM: trailing 12 months
We're not expecting Applied DNA Sciences to pay a dividend over the next 12 months.
Applied DNA Sciences's shares were split on a 1:40 basis on 31 October 2019. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Applied DNA Sciences shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for Applied DNA Sciences shares which in turn could have impacted Applied DNA Sciences's share price.
Over the last 12 months, Applied DNA Sciences's shares have ranged in value from as little as $3.2 up to $13.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Applied DNA Sciences's is 0.9235. This would suggest that Applied DNA Sciences's shares are less volatile than average (for this exchange).
Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally.
Lido’s liquid staking allows investors holding LUNA and less than 32 ETH to reap the rewards of DeFi staking.
Downturns often let you buy fundamentally strong stocks at bargain prices, but mind the fundamentals and consider these 3 rules.
The crypto market wiped out $1.5 trillion in value in just three months.
Bitcoin breached the $40,000 price level and may plummet lower as Russia signals a potential ban.
Cardano’s first metaverse project is available to investors now — if you can find a piece of digital land on sale. Plots sold fast despite the project’s early stage limitations.
Walmart files trademarks with the goal to issue its own cryptocurrency and NFTs for use in its digital stores.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.